Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …

Background Aspirin and clopidogrel monotherapies are effective treatments for preventing
vascular disease. However, new evidence has emerged regarding the use of combined …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

Background and Purpose—In the Secondary Prevention of Small Subcortical Strokes
(SPS3) trial, addition of clopidogrel to aspirin was associated with an unexpected increase …

Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

PURPOSE: Clopidogrel is more effective than aspirin in preventing recurrent vascular
events, but concerns about its cost-effectiveness have limited its use. We evaluated the cost …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …

Background—We studied the benefits and risks of adding clopidogrel to different doses of
aspirin in the treatment of patients with acute coronary syndrome (ACS). Methods and …